Researchers in pharmaceutical and biotechnology sectors now have access to advanced, customizable aging mouse models designed to enhance drug discovery and understanding of age-related diseases. CD BioSciences has launched a comprehensive platform that enables precise modeling of aging pathways through sophisticated gene-editing techniques.
Mouse models represent critical experimental tools in aging research due to their genetic similarities to humans and ability to simulate complex biological processes. The new offering from CD BioSciences integrates multiple aging research approaches, including D-galactose-induced senescence models, total body irradiation models, ozone-induced senescence models, and genetically engineered models.
The platform's key strengths include precision-driven customization using CRISPR-Cas9 technology, which allows researchers to simulate specific aging pathways, metabolic disorders, and neurodegenerative conditions. By providing models that replicate age-related comorbidities such as sarcopenia, osteoarthritis, and chronic kidney disease, the company aims to significantly reduce experimental timelines.
CD BioSciences offers a comprehensive range of mouse strains, from standard C57BL/6 and BALB/c to advanced gene-modified models. This diversity enables researchers to select optimal models based on specific research requirements, potentially accelerating discoveries in oncology, immunology, and metabolic disease research.
The company's end-to-end support includes model design, biomarker analysis, and AI-driven metabolic profiling. This comprehensive approach provides researchers with seamless collaboration opportunities and expedited research processes focused on longevity and age-specific disease mechanisms.
Researchers can leverage these aging models to investigate critical processes such as identifying biomarkers for age-related disease onset and assessing the efficacy and safety of potential anti-aging therapies. The platform's scalability and compliance with global regulatory standards further enhance its potential impact on preclinical drug development.
